Spotlights

Memorandum

Update There is exciting news in Auxesis Pharma. Trademarks, new areas of application, clinical studies and trials, production facilities, to name a few. Complete pdf

Read More »

Share Issue Offering

Do you want to join the journey? AUXESIS PHARMA HOLDING AB (publ) is increasing its stock with maximum 600.000 shares at a price of SEK 30/share.Duration for purchasing shares is from 10th

Read More »

Public Limited Company

AUXESIS PHARMA HOLDING AB (publ) is now registered with the Swedish Companies Registration Office as a Public Limited Company (PLC) with a share capital of SEK 500,000. A

Read More »

Scenario valuation

Scenario valuation of the shares in AUXESIS PHARMA HOLDING AB (publ) prior to the launch of the company’s analgesic product ASA.P® is now available. One-Pager

Read More »

New Board Members

Welcome as Board Members – Charlotta Larsson and Rune Nordström. Thank you to all shareholders for a great meeting and big thanks to Lars Larsson

Read More »

Exclusive Licensing Agreement

Auxesis Pharma Holding AB has signed a license agreement with Pharma America Corp. in Florida, for a powerful introduction to the entire Americas. The ASA.P®

Read More »

SME status/EMA

En beviljad SME status från EMA betyder att bolaget får lättare tillgång till regulatorisk, finansiell och administrativ assistans från EMA inom utveckling av företagets produkter

Read More »